Insider Selling: Artivion (NYSE:AORT) CEO Sells $2,026,500.00 in Stock

Posted by Geri Gentry on Aug 20th, 2026

Artivion, Inc. (NYSE:AORT – Get Free Report) CEO James Mackin sold 70,000 shares of Artivion stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the completion of the sale, the chief executive officer owned 877,275 shares of the company’s stock, valued at approximately $25,397,111.25. The trade was a 7.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Artivion Price Performance

NYSE:AORT traded down $0.82 during trading hours on Thursday, reaching $28.00. 262,630 shares of the company were exchanged, compared to its average volume of 595,501. The business has a 50 day moving average of $24.77 and a 200 day moving average of $30.24. Artivion, Inc. has a 1-year low of $19.16 and a 1-year high of $48.25. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.47 and a quick ratio of 2.51. The company has a market capitalization of $1.37 billion, a P/E ratio of -399.94 and a beta of 1.25.

Artivion (NYSE:AORT – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. The firm had revenue of $125.76 million during the quarter, compared to analysts’ expectations of $119.99 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. Research analysts forecast that Artivion, Inc. will post 0.45 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently commented on AORT. Canaccord Genuity Group boosted their price target on Artivion from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday. Citizens Jmp lowered their target price on Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a research note on Friday, May 8th. Citigroup restated a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st. Stifel Nicolaus set a $45.00 price target on Artivion in a report on Monday, June 1st. Finally, Wall Street Zen downgraded shares of Artivion from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $44.83.

Get Our Latest Research Report on AORT

Institutional Investors Weigh In On Artivion

Several institutional investors and hedge funds have recently modified their holdings of AORT. Royal Bank of Canada boosted its holdings in Artivion by 73.1% in the first quarter. Royal Bank of Canada now owns 93,676 shares of the company’s stock valued at $3,430,000 after purchasing an additional 39,553 shares during the last quarter. Vanguard Group Inc. increased its holdings in Artivion by 4.7% during the 4th quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock worth $144,588,000 after purchasing an additional 141,030 shares during the last quarter. Orbimed Advisors LLC purchased a new stake in Artivion during the 1st quarter worth approximately $5,530,000. UBS Group AG raised its position in shares of Artivion by 37.0% in the 4th quarter. UBS Group AG now owns 279,675 shares of the company’s stock valued at $12,756,000 after purchasing an additional 75,606 shares in the last quarter. Finally, Fifth Third Bancorp raised its position in shares of Artivion by 58,029.7% in the 1st quarter. Fifth Third Bancorp now owns 123,235 shares of the company’s stock valued at $4,513,000 after purchasing an additional 123,023 shares in the last quarter. Hedge funds and other institutional investors own 86.37% of the company’s stock.

About Artivion

(Get Free Report)

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.